PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

CORRELATION BETWEEN CYCLIN D1 EXPRESSION AND RENAL CELL CANCER (RCC) PROGNOSTIC FACTORS. INITIAL STUDY
Article published in Urologia Polska 2000/53/1.

authors

Sławomir Chaberek 1, Agnieszka D. Kolasińska 2, Kerstin Rolfe 2, Marek Żabiński 3, Danuta Shafie 3, Gidon Lieberman 2, Jarosław Ćwikła 1
1 Department of Radiology and Nuclear Medicine, SPSK 2, Otwock
Head of Department: Dr. J. Szawdyn
2 Academic Department of Obstetrics and Gynaecology Royal Free Hospital, London, UK
Head of Department: Prof. R. McLean
3 Department of Pathology and Urology, Departmental Hospital, Olsztyn
Head of Department: Dr. J. Gugała and Dr. M. Żabiński

keywords

kidney RCC cyclin D1 immunohistochemistry image analysis

summary

Objective. In this initial study we have evaluated the correlation between
cyclin D1 expression, morphological characteristics and outcome in patients
with renal cell carcinoma (RCC).
Patients and methods. Samples where obtained after total nephrectomy
from 12 patients (mean age 57; SD 5. 43; male to female ratio 1: 1; age range
45-66) all with histological confirmation of RCC. Staining of cyclin D1 was
evaluated using immunohistochemistry (IHC). A positive study was consid-
ered if more than 20% ofpositive nuclei, were calculated both manually and
automated. IHC results were compared to a range of RCC Prognostic factors
age of patients, size of the tumour, TNM grading and Robson's score
mean follow-up time was 30. 2 months (SD 7. 36).
Results. The histological types were as follows: 8 clear cell, 2 granular cell
and 2 papillary carcinomas. Cyclin D1 expression was detected in 9 patients
Our findings were that there was no significant difference between cyclin D1
expression and histological type of the tumour. There was no significant dif-
ference between cyclin D1 expression and grading scales using TNM or Rob-
son's classification. There was no correlation between cyclin D1expression
and the above Prognostic factors of RCC. Finally, there was no significant
difference between cyclin D1 expression in patients who died and those who
survived (p = 0. 29).
Conclusion. Analysis of cyclin D1 expression in RCC by IHC is a simple and
easily reproducible technigue (manually and automated). Our initial results
indicate that most RCC express cyclin Dr There was no correlation between
cyclin D1 expression. and standard Prognostic factors of RCC.

references

  1. [1] Cronin, K. J., Williams, N. N., Kerin, M. J., Creagh, T. A., Dervan, P.
  2. A., Smith, J. M., Fitzpatrick, J. M.: Proliferating cell nuclear antigen: a new
  3. prognostic indicator in renal cell carcinoma. J. Urol. 1994,152, 834-836.
  4. [2] Delahunt, B., Bethwaite, P. B., Thornton, A., Ribas, J. L.: Proliferation of
  5. renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody label-
  6. ing. Correlation with clinical outcome. Cancer 1995, 75, 2714-2719.
  7. [3] Gelb, A. B., Sudilovsky, D., Wu, C. D., Weiss, L. M., Medeiros, L. J.:
  8. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, andp53
  9. protein expression as prognostic indicators in patients with locally confined renal
  10. cell carcinoma. Cancer 1997, 80,1768-1775.
  11. [4] Grignon, D. J., Abdel-Malak, M., Mertens, W., Koster, J., Keeney, M.,
  12. Sakr, W., Shepherd, R. R.: Prognostic significance of cellular proliferation in
  13. renal cell carcinoma: a comparison of synthesis-phase fraction and proliferating cell
  14. nuclear antigen index. Mod. Pathol. 1995,1,18-24.
  15. [5] Hedberg, Y., Davoodi, E., Roos, G., Ljungberg, B., Lanberg, G.: Cyclin
  16. D1 overexpression and cell cycle defects are common in human renal cell carcinomas.
  17. Proc. Amer. Cancer Soc, Suppl. Cancer Res. 1998, 3013.
  18. [6] Hindermann, W., Berndt, A., Wunderlich, H., Katenkamp, D., Kos-
  19. mehl, H.: Quantitative evaluation of apoptosis and proliferation in renal cell carci-
  20. noma. Correlation to tumour subtype, cytological grade according to thoenes-classi-
  21. fication and the occurrence of metastasis. Pathol. Res. Pract. 1997,193,1-7.
  22. [7] Jochum, W., Schroder, S., al-Taha, R., August, C, Gross, A. J., Berger,
  23. J., Padberg, B.C.: Prognostic significance of nuclear DNA content and prolifer-
  24. ative activity in renal cell carcinomas. A clinicopathologic study of 58 patients us-
  25. ing mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer 1996, 77,
  26. 514-521.
  27. [8] de Kernion, J, B.: Renal tumors,In:PC. Walsh (ed.): Campbell's urology. 5th ed.,
  28. vol. 2, P. Sounders, Philadelphia 1986,1294-1342.
  29. [9] Larsson, P., Roos, G., Stenling, R., Ljungberg, B.: Tumor-cell proliferation
  30. and prognosis in renal-cell carcinoma. Int. J. Cancer 1993, 55, 566-570.
  31. [10] Matsushime, H., Roussel, M. F., Ashmun, R. A., Sherr, C. J.: Colony-
  32. stimulating factor 1 regulates novel cyclin during the G1 phase of the cell cycle. Cell
  33. 1991, 65, 701.
  34. [11] Papadopoulos, I., Weichert-Jacobsen, K., Sprenger, E., Wacker, H. H.:
  35. DNA content and the proliferation marker Ki-67 as prognostic indicators in renal
  36. cell carcinoma. Urol. Int. 1994, 53,181-185.
  37. [12] de Riese, W. T., Crabtree, W. N., Allhoff, E. P., Werner, M., Liedke, S.,
  38. Lenis G., Atzpodien, J., Kirchner, H.: Prognostic significance of Ki-67 im-
  39. munostaining in nonmetastatic renal cell carcinoma. J. Clin. Oncol. 1993,11,1804-
  40. 1808.
  41. 13] Robson, C, Churchill, B. M., Anderson, W.: The results of radical nephrecto-
  42. my for renal cell carcinoma. J. Urol. 1969,101, 297-301.
  43. 14] Stenzl, A., de Kernion, J.: Pathology, biology and clinical staging of renal cell
  44. carcinoma. Semin. Oncol. 1989,16, 3-11.
  45. [15] Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi,
  46. C, Lavin, Ph., Draetta, G., Pagano, Loda, M.: The cell cycle inhibitor p27
  47. is an independent prognostic marker in small (Tlab) invasive breast carcinomas.
  48. Cancer Res. 1997, 57, 1259-1263.
  49. [16] Tanioka, F., Hiroi, M., Yamane, T., Hara, H.: Proliferating cell nuclear an-
  50. tigen (PCNA), immunostaining and fiow cytometric DNA analysis of renal cell
  51. carcinoma. Zentr. Pathol. 1993,139,185-193.
  52. [17] Tannapfel, A., Hahn, H. A., Katalinic, A., Fietkau, R. J., Kuhn, R.,
  53. Wittekind, C. W.: Incidence of apoptosis, cell proliferation andp53 expression in
  54. renal cell carcinomas. Anticancer Res. 1997, (2A) 1155-1162.
  55. [18] Usubutun, A., Ayhan, A., Uygur, M. C, Ozen, H., Toklu, C, Ruacan, S.:
  56. Prognostic factors in renal cell carcinoma. J. Exp. Clin. Cancer Res. 1998,17,77-81.
  57. [19] DeVita, V. T.: Principles and practice of oncology. V. T. DeVita, S. Hellman, S.
  58. A. Rosenberg. Lippincrott (eds.). Philadelphia 1989, 276-300.
  59. [20] Yasunaga, Y., Shin, M., Miki, T., Okuyama, A., Aozasa, K.: Prognostic
  60. factors of renal cell carcinoma: a multivariate analysis. J. Surg. Oncol. 1998, 68,
  61. 11-18.
  62. [21] Yoshino, S., Kato, M., Okada, K.: Evaluation of the prognostic significance of
  63. microvessel count and tumor size in renal cell carcinoma. Int. J. Urol. 1998,5,119-
  64. 123.